Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Opioid Use Disorder, Opioid Use, Insomnia, Orexin Antagonist
Interventions
Placebo, Lemborexant 10 MG
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 4 Interventional Results available

Lemborexant Shift Work Treatment Study

NCT05344443
Conditions
Shift-Work Related Sleep Disturbance
Interventions
Lemborexant, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cue-reactivity, Cannabis Use Disorder, Functional MRI, Orexin Antagonist
Interventions
Suvorexant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

NCT01243060
Conditions
Healthy Volunteers
Interventions
Almorexant, Zolpidem 10mg, Placebo
Drug
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
19 Years to 39 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more
Conditions
Suicide Risk, Major Depressive Disorder (MDD)
Interventions
Suvorexant (dual orexin receptor antagonist)
Drug
Lead sponsor
Marianne Goodman
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Recruiting Phase 2 Interventional Accepts healthy volunteers

DORA and LP in Alzheimer's Disease Biomarkers

NCT06274528
Conditions
Alzheimer Disease
Interventions
Lemborexant 10 mg, Lemborexant 20mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Advanced Malignant Solid Neoplasm, Delirium, Hematopoietic and Lymphatic System Neoplasm, Insomnia
Interventions
Best Practice, Electronic Health Record Review, Interview, Questionnaire Administration, Suvorexant
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota